Panbela Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OTC.Pink
Panbela Therapeutics reported a net loss of $21.4 million for the nine months ended September 30, 2024, while navigating financial challenges and making progress in its clinical trials.
OTC.Pink
Panbela Therapeutics reported its Q2 2024 financial results, highlighting increased research and development expenses due to the ASPIRE trial, while also facing significant liquidity challenges and a potential CRO termination.
OTC.Pink
Panbela Therapeutics reported a net loss of $7.1 million for Q1 2024, alongside ongoing financial and operational challenges including a recent delisting from Nasdaq.